CONNECTA Therapeutics

    CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support

    CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients CONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech advancing a clinical-stage FXS program. 9 September 2025...
    Parc Científic de Barcelona Baldiri Reixac, 10-12 08028 Barcelona Spain